Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (2493)	5/15/1998 4:15:00 PM
From: Anthony Wong	Respond to of 9523

Study Says Bristol-Myers Blood-Pressure Drug Better Than Pfizer's May 15, 1998 3:35 PM NEW YORK -(Dow Jones)- A study conducted by the University of Tennessee-Memphis showed that Bristol-Myers Squibb Co.'s Monopril product reduced the risk of a heart attack or stroke in patients with diabetes and hypertension by 51% compared to Pfizer Inc.'s Norvasc. The university said physicians have assumed that if a drug can reduce blood pressure, it should offer equal protection against cardiovascular events, but this study "suggests blood pressure reduction alone might not be a sufficient marker of drug efficacy." The university said two additional trials are under way or planned as follow-ups to the completed study. The study was published in the April issue of Diabetes Care and presented at the American Society of Hypertension annual meeting. Monopril is an angiotensin converting enzyme, or ACE, inhibitor fosinopril. Norvasc is a long-acting calcium channel blocker, or CCB, amlodipine. CCBs are among the most frequently used therapies for preventing cardiovascular events in diabetic hypertensive patients, according to the university. Bristol-Myers Squibb (BMY) and Pfizer (PFE) officials declined comment. The study focused on 380 patients with diabetes and hypertension for up to three-and-a-half years. A randomized, double-blind clinical trial of 104 patients is under way as a further study. An additional follow-up study that will examine 307 hypertensive patients with left ventricular hypertrophy is expected to be complete by early 1999, the university said. Copyright (c) 1998 Dow Jones & Company, Inc. All Rights Reserved.